Cargando…
A Synthetic Peptide CTL Vaccine Targeting Nucleocapsid Confers Protection from SARS-CoV-2 Challenge in Rhesus Macaques
Background: Persistent transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has given rise to a COVID-19 pandemic. Several vaccines, conceived in 2020, that evoke protective spike antibody responses are being deployed in mass public health vaccination programs. Recent data su...
Autores principales: | Harris, Paul E., Brasel, Trevor, Massey, Christopher, Herst, C. V., Burkholz, Scott, Lloyd, Peter, Blankenberg, Tikoes, Bey, Thomas M., Carback, Richard, Hodge, Thomas, Ciotlos, Serban, Wang, Lu, Comer, Jason E., Rubsamen, Reid M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8158516/ https://www.ncbi.nlm.nih.gov/pubmed/34070152 http://dx.doi.org/10.3390/vaccines9050520 |
Ejemplares similares
-
An effective CTL peptide vaccine for Ebola Zaire Based on Survivors’ CD8+ targeting of a particular nucleocapsid protein epitope with potential implications for COVID-19 vaccine design
por: Herst, C.V., et al.
Publicado: (2020) -
Anti-IL-6 Versus Anti-IL-6R Blocking Antibodies to Treat Acute Ebola Infection in BALB/c Mice: Potential Implications for Treating Cytokine Release Syndrome
por: Rubsamen, Reid, et al.
Publicado: (2020) -
Paired SARS-CoV-2 spike protein mutations observed during ongoing SARS-CoV-2 viral transfer from humans to minks and back to humans
por: Burkholz, Scott, et al.
Publicado: (2021) -
Survivin Expression in Luminal Breast Cancer and Adjacent Normal Tissue for Immuno-Oncology Applications
por: Wright, Sharon, et al.
Publicado: (2023) -
Survivin (BIRC5) Peptide Vaccine in the 4T1 Murine Mammary Tumor Model: A Potential Neoadjuvant T Cell Immunotherapy for Triple Negative Breast Cancer: A Preliminary Study
por: Burkholz, Scott R., et al.
Publicado: (2023)